Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Holding AMGN?
Track your performance easily
AMGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$253.30 - $346.85
Previous Close$264
Volume1.52M
Average Volume (3M)3.26M
Market Cap
$141.91B
Enterprise Value$193.30B
Total Cash (Recent Filing)$9.01B
Total Debt (Recent Filing)$60.40B
Price to Earnings (P/E)33.8
Beta0.48
Next Earnings
Feb 04, 2025EPS Estimate
$5.04Next Dividend Ex-Date
Feb 14, 2025Dividend Yield3.42%
Share Statistics
EPS (TTM)7.81
Shares Outstanding537,532,723
10 Day Avg. Volume4,746,853
30 Day Avg. Volume3,262,796
Standard Deviation0.07
R-Squared0.17
Alpha0.00131
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)18.86
Price to Sales (P/S)4.35
Price to Cash Flow (P/CF)9.90
P/FCF Ratio8.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.94
Enterprise Value/Gross Profit9.79
Enterprise Value/Ebitda14.34
Forecast
1Y Price Target
$340.76Price Target Upside28.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Amgen News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe likelihood of success for AMGN's olpasiran candidate in its clinical trial is projected to be high, which may boost expectations.
Obesity And Diabetes TreatmentMariTide data firmly establishes Amgen as a competitor in obesity and diabetes indications, showing compelling weight loss in both indications.
Stock ValuationThe Outperform thesis on AMGN is supported by fundamental analysis suggesting the shares are undervalued given the opportunity contribution of revenue from the recently closed Horizon transaction.
Bears Say
Clinical Data ConcernsTolerability data look worse than tirzepatide, with high rates of nausea and vomiting reported.
EarningsThe EPS growth estimate has been lowered due to higher investment spending assumptions.
Market CompetitionCommercial dynamics in the GLP-1/obesity space make it difficult for late entrants like MariTide to capture meaningful market share.
---
Ownership Overview
0.18% Insiders
21.20% Mutual Funds
18.53% Other Institutional Investors
31.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $253.30 and its highest was $346.85 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Feb 04, 2025 which is in 41 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Oct 30, 2024. The company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.274 by $0.306.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3.42%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is $5.04.
How many shares outstanding does Amgen have?
Amgen has 537,532,700 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $5.58 in its last earnings report, beating expectations of $5.274. Following the earnings report the stock price went up 1.463%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 5B.
---
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMGN Company Deck
---
AMGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong performance across key product segments, particularly in oncology and rare diseases, with substantial revenue growth and expansion plans. However, there were noted challenges with declining sales in certain legacy products like Enbrel and Otezla. Overall, the sentiment was positive with a focus on continued growth and innovation.Read More>---
AMGN Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
AMGN Stock 12 Month Forecast
Average Price Target
$340.76
▲(28.84% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
21/34 ratings generated profit
1 Year Average Return
+9.41%
reiterated a buy rating 23 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 61.76% of your transactions generating a profit, with an average return of +9.41% per trade.
---